Ignite Creation Date:
2024-05-05 @ 10:06 PM
Last Modification Date:
2024-10-26 @ 10:14 AM
Study NCT ID:
NCT01034644
Status:
COMPLETED
Last Update Posted:
2014-07-31
First Post:
2009-12-09
Brief Title:
Pharmacogenetic Trial and Long-term Follow-up of the PRISMS Trial PRISMS-15
Sponsor:
Merck KGaA Darmstadt Germany
Organization:
Merck KGaA Darmstadt Germany
Study Overview
Official Title:
A Multinational Multicenter Single Visit Exploratory Pharmacogenetic Trial and Long-term Follow-up of the PRISMS Prevention of Relapses and Disability by Interferon Beta-1a Subcutaneously in Multiple Sclerosis Trial
Status:
COMPLETED
Status Verified Date:
2011-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
PRISMS-15
Brief Summary:
This study PRISMS-15 is a single visit exploratory pharmacogenetic trial and long-term follow-up of the PRISMS Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis trial
The aim of this trial is to provide additional data on the driving factors of IFN beta response and the long-term outcomes of Rebif treatment
This is a Phase IV trial involving subjects who previously participated in the PRISMS trial To address the trial objectives a single visit will be performed at least 3 months after the onset of the last relapse
The aim of this trial is to provide additional data on the driving factors of IFN beta response and the long-term outcomes of Rebif treatment
This is a Phase IV trial involving subjects who previously participated in the PRISMS trial To address the trial objectives a single visit will be performed at least 3 months after the onset of the last relapse
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None